As a Principal with Cello Health BioConsulting, Danielle leads projects focused on market access strategy, opportunity assessments, identification and evaluation of partnering opportunities, and asset valuation. She heads the antibiotic practice and co-leads the autoimmune and inflammatory practice; however, her experience spans the therapeutic landscape.
Prior to joining Cello Health BioConsulting in 2011, Danielle was a Scientist in the Bioanalytical Development group at an emerging biotech company in New Jersey where she was responsible for the design, development, and validation of a number of immuno- and cell-based assays for use in preclinical and early phase clinical studies for metabolic and autoimmune bone diseases. Danielle was also involved in performing competitive intelligence for the Business Development team to identify potential partners for licensing, as well as competitors in the peptide therapeutic space.
Danielle received a Masters Degree in Cell and Developmental Biology and an MBA with concentrations in Pharmaceutical Management and Marketing from Rutgers University. Her Masters research focused on the NAD-dependent deacetylase, sirtuin-1, and its activity in colon, breast, and pancreatic cancer. She holds a B.S. in Biology from The College of New Jersey.
Kirstie Norgate, Account Director, Cello Health Insight on the supportive team environment, and the opportunity to travel on multinational projects, expanding her understanding of clients’ global challenges
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us